Turnaround time for the EONIS Q workflow from sample-in to result is approximately three hours
Revvity has announced the launch of its EONIS Q system, a CE-IVD declared platform enabling laboratories in countries that accept the CE marking to adopt molecular testing for spinal muscular atrophy (SMA) and severe combined immunodeficiency (SCID) in newborns.
For both inherited conditions, immediate detection is critical to advancing a positive outcome. For SMA, disease modifying therapies exist to stop the progression of the disease, and for SCID, immunoglobulin treatments combined with stem cell therapies can potentially cure a child, if intervention comes in time. However, to date, molecular testing for these and other congenital disorders is relatively low, due in part to cost restrictions and the technical expertise required to perform and interpret these tests.
The EONIS Q system simplifies and streamlines molecular testing for SMA and SCID with an innovative workflow, inclusive of the EONIS Q96 instrument, the EONIS SCID-SMA kit and EONIS EASI software.
Petra Furu, general manager of reproductive health, Revvity said, “Helping children get a healthier start to life is at the heart of our work and making molecular testing for inherited conditions like SMA and SCID more accessible can help further that aim. Without compromising quality, speed or test result accuracy, the EONIS Q system is designed to break down some of the common barriers that prevent newborn screening labs from adopting these tests.”
Turnaround time for the EONIS Q workflow from sample-in to result is approximately three hours, and compared to conventional wet qPCR solutions, the system exceeds industry standards in software capability. There are no wash steps required and fewer pipetting and centrifuging steps involved, further reducing hands-on time. Compared to other methods, the EONIS Q system uses fewer consumables and one-time use plasticware, further optimising resource and cost efficiencies for labs looking to adopt the system.